Deferasirox treatment for myelodysplastic syndromes: "real-life" efficacy and safety in a single-institution patient population

Annals of Hematology
Massimo BrecciaGiuliana Alimena

Abstract

We here describe a single-institution experience on 40 patients with myelodysplastic syndromes (MDS) consecutively treated with deferasirox at the dose of 10-30 mg/kg/day according to Consensus Guidelines on Iron Chelation Therapy, outside of clinical trials. Serum ferritin (SF) was measured monthly, and safety assessment included monitoring of adverse events during treatment and of liver and renal parameters. Median SF at baseline of the 40 patients was 2,878 ng/ml. Median dose of deferasirox was 1,125 mg/day. At a median follow-up of 12 months of treatment, there was a significant reduction in SF from baseline, the median value being 1,400 ng/ml (p = 0.001). Interruptions due to toxicity were recorded in 40 % of patients: most common adverse events were diarrhoea (five patients, 12.5 %) and skin rash (four patients, 10 %). Seven patients had increased serum creatinine values >33 % above baseline, but there were no progressive increases. Four patients (three refractory anaemia and one refractory anaemia with excess blasts type 1) had a reduction of transfusion requirement (from a median of 5 to 1 unit/month) according to International Working Group 2006 criteria, with mean Hb value increasing from 8.5 to 10.5 g/dl, and mean Hb...Continue Reading

References

Aug 30, 2008·Journal of the American College of Cardiology·Hessel F GroenveldPeter van der Meer
Nov 6, 2009·The New England Journal of Medicine·Ayalew Tefferi, James W Vardiman
Dec 17, 2009·Hemoglobin·John B Porter
Feb 13, 2010·Leukemia Research·V SantiniUNKNOWN Italian Society of Hematology
Mar 30, 2010·Leukemia Research·Heather A Leitch
Apr 28, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Stuart L GoldbergMarianne Laouri

❮ Previous
Next ❯

Citations

Feb 19, 2013·Annals of Hematology·Massimo Breccia, Giuliana Alimena
Feb 26, 2013·Current Treatment Options in Oncology·Karen Seiter
Feb 11, 2014·Best Practice & Research. Clinical Haematology·David P Steensma, Norbert Gattermann
Mar 17, 2016·South Asian Journal of Cancer·Sachi Jain Taran, Rakesh Taran
Feb 18, 2014·Critical Reviews in Oncology/hematology·Sally TemrazAli Taher
Sep 3, 2013·Expert Review of Hematology·Mhairi MitchellAmer M Zeidan
Mar 20, 2014·Expert Review of Anticancer Therapy·Drorit G Merkel, Arnon Nagler
Oct 3, 2013·Expert Review of Hematology·Gabriele GugliottaGianantonio Rosti
Dec 22, 2017·Anais Brasileiros De Dermatologia·Asude Kara PolatYelda Dere
Jun 1, 2021·Critical Reviews in Oncology/hematology·Cecilia H Kim, Heather A Leitch

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.